Details for New Drug Application (NDA): 083125
✉ Email this page to a colleague
NDA 083125 describes PROPOXYPHENE HYDROCHLORIDE, which is a drug marketed by Alra, Impax Labs, Ivax Sub Teva Pharms, Mutual Pharm, Mylan, Nexgen Pharma Inc, Par Pharm, Purepac Pharm, Pvt Form, Roxane, Sandoz, Teva, Valeant Pharm Intl, Vintage Pharms, Watson Labs, West Ward, Whiteworth Town Plsn, and Warner Chilcott, and is included in thirty-two NDAs. Additional details are available on the PROPOXYPHENE HYDROCHLORIDE profile page.
The generic ingredient in PROPOXYPHENE HYDROCHLORIDE is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
The generic ingredient in PROPOXYPHENE HYDROCHLORIDE is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
Summary for 083125
| Tradename: | PROPOXYPHENE HYDROCHLORIDE |
| Applicant: | Sandoz |
| Ingredient: | propoxyphene hydrochloride |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 65MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
